OpenAI acquires AI pharmaceutical start-up Orchestra Bio and incorporates the "R&D" Agent into the life sciences territory. OpenAI has made another move, this time focusing on the organizational aspects of drug R&D.

OpenAI acquired Orchestra Bio, an AI pharmaceutical start-up, and incorporated the "R&D" Agent into the life sciences territory. OpenAI has made another move, this time focusing on the organizational aspects of drug research and development. It acquired Orchestra Bio, a start-up company specializing in AI collaborative management of drug development projects, and integrated its team and technology into its life science research platform Rosalind. Andy Xu, CTO of Orchestra Bio, has an education background at Peking University. The main direction of this company is to use AI Agent to undertake project management tasks such as task sorting, progress tracking, risk prediction, and cross-team collaboration in the entire drug development process. In other words, it does not conduct experiments for scientists, but manages the extremely complex matter of "how to develop drugs" for the team. This acquisition is not an isolated move. OpenAI has been playing chess in the field of life sciences for many years: it has successively launched biologically specialized models, the GPT-Rosalind series of dedicated inference models, the supporting scientific research work environment Rosalind Workbench, and is also promoting related biodefense plans. The R&D tool chain is almost complete, but the missing link is "organizational coordination and project implementation" - the inclusion of Orchestra Bio this time just makes up for this shortcoming, adding an additional layer of intelligent management that can schedule, monitor progress, and predict risks between model capabilities and actual R&D advancement. What’s interesting is the time window. At the same time, Anthropic also announced its own new progress in biological research. Its focus is on building a closed loop of drug discovery from AI hypothesis generation to wet experimental verification. Two leading AI companies, one focusing on "organizational collaboration" and the other focusing on "hypothesis to verification", are competing for a position on the AI ​​​​pharmaceutical track with completely different priorities. via AI News (author: AI Base)